The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Bispecifics in lymphoma treatment: a rapidly evolving field
Eliza Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Research Institute at Austin Health, Melbourne, Australia, comments on the growing field of bispecific antibodies in lymphoma treatment, highlighting the four main agents that have entered standard of care: glofitamab, epcoritamab, mosunetuzumab, and odronextamab. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The bispecifics field in lymphoma is a huge and proliferative area. There is a large expansion of all sorts of bispecifics. The main ones that have entered standard of care are CD3 and CD20, and there are four main agents within this class: glofitamab, epcoritamab, mosunetuzumab, and odronextamab. I think we have a lot to learn when giving these. I think there is a class effect but there are subtle differences in the amount of side effects, particularly cytokine release syndrome and infection that we are worried about, cytopenias...
The bispecifics field in lymphoma is a huge and proliferative area. There is a large expansion of all sorts of bispecifics. The main ones that have entered standard of care are CD3 and CD20, and there are four main agents within this class: glofitamab, epcoritamab, mosunetuzumab, and odronextamab. I think we have a lot to learn when giving these. I think there is a class effect but there are subtle differences in the amount of side effects, particularly cytokine release syndrome and infection that we are worried about, cytopenias. We don’t currently have any very validated strong biomarkers for response or toxicity at the moment and there’s a lot of work going on into that but we really need those to better understand who should have these agents and who should have alternatives. Also mechanisms of resistance. We know that the T-cells get very exhausted so we really need to deep dive into that. We have a lot of newer agents that target CD19, CD22, other agents as well that are coming through targeting other components of the malignant cancer cell and then of course upregulating the immune system to kill those via that mechanism. It’s a super exciting area. I can’t pick my favorite. I don’t think I have one, but I’m just excited that we have this new option available in the clinic now and that there’s more to come.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video
Read more...
